Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03185065 (ClinicalTrials.gov)	October 4, 2017	9/6/2017	Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis	Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis	Fatigue in Multiple Sclerosis	Drug: Amantadine;Drug: Modafinil;Drug: Methylphenidate;Drug: Placebos	Johns Hopkins University	Patient-Centered Outcomes Research Institute	Completed	18 Years	N/A	All	141	Phase 3	United States
2	NCT02286557 (ClinicalTrials.gov)	October 2014	16/10/2014	Testing the Effects of Methylphenidate on Multiple Sclerosis	Testing the Effects of Methylphenidate on Cognitive Fatigue in Multiple Sclerosis: a Double-blind, Placebo-controlled, Randomized Clinical Trial	Fatigue in Multiple Sclerosis	Drug: Methelphenidate;Drug: Placebo	Kessler Foundation	NULL	Not yet recruiting	18 Years	65 Years	Both	36	Phase 2	NULL
3	NCT01896700 (ClinicalTrials.gov)	July 2013	8/7/2013	Methylphenidate to Improve Balance and Walking in MS	Methylphenidate to Improve Balance and Walking in MS	Multiple Sclerosis	Drug: Methylphenidate;Drug: Placebo	Oregon Health and Science University	Portland VA Medical Center	Completed	20 Years	65 Years	All	24	Phase 2/Phase 3	United States
4	NCT01879202 (ClinicalTrials.gov)	December 2012	7/11/2012	Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis	Methylphenidate Modified-release as Treatment of MS-associated Fatigue. A Single-center Randomized Double-blind Placebo-controlled Study.	Multiple Sclerosis;Fatigue	Drug: Methylphenidate modified release;Drug: Maltodextrin	Medical University of Vienna	NULL	Recruiting	18 Years	N/A	Both	96	Phase 2	Austria
5	EUCTR2012-003418-15-AT (EUCTR)	23/10/2012	09/11/2012	Methylphenidate modified release as treatment of MS-associated fatigue.	Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial.	Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic approaches like exercise, cooling procedures and energy conservation programs and as second step pharmacologic therapy. Until now, Amantadine, Modafinil or antidepressants have been used off-label among others, with some success. Until now, methylphenidate has been successfully used to treat fatigue in HIVand parkinson´s disease, data on its efficacy in MS are not available.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ritalin LA 20mg capsules Product Name: Methylphenidate modified release 20 mg INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE Trade Name: Ritalin LA 30mg capsules Product Name: Methylphenidate modified release 30 mg INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE Trade Name: Ritalin LA 40mg capsules Product Name: Methylphenidate modified release 40 mg INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE	Medizinische Universität Wien	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Austria

先頭へ